MLYS
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 49.1, with 0/3 trend checks passing.
MLYS with MA50 and MA200
Key levels & signals
MLYS valuation multiples (TTM)
MLYS analyst consensus
Mineralys Therapeutics, Inc. (MLYS) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $27.17, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 0.6% and below the 200-day moving average by 15.6%.
MLYS currently has an RSI reading of 49.1, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing MLYS next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about MLYS
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.